Bounty names winners of ‘Mess Behind Glory’ contest with help from Shawn Johnson, mom
CINCINNATI — Olympic gold-medal gymnast Shawn Johnson and her mother announced the winners of Bounty’s "Mess Behind the Glory" contest.
Launched back in late April, the contest — which was launched as part of Bounty’s Bring It campaign — asked moms to share 60- to 90-second videos describing their child’s athletic dreams and how they let them “Bring It” for the chance to win prizes that help their children achieve their dreams. Johnson and mother Teri unveiled the names of the top 10 winners, one of whom earned the grand prize, a $5,00 grant. All of the winners received the Ultimate London 2012 Olympic Games Viewing Party, as well as a year’s supply of Bounty.
To see the winning video and learn more about Bounty and the "Bring It" campaign, log on to Bounty’s Facebook page.
Hospira relaunches chemotherapy drug
LAKE FOREST, Ill. — Hospira has relaunched a generic chemotherapy drug for the U.S. market, the generic drug maker said Thursday.
The company, which specializes in generic injectables, announced the relaunch of oxaliplatin, a version of Sanofi’s Eloxatin.
Hospira originally launched oxaliplatin in August 2009 after a court ruled in its favor in a patent-infringement suit filed by Sanofi. Sanofi and Hospira later settled the suit in 2010, requiring Hospira to suspend sales of the drug in June 2010, but allowing it to relaunch ahead of the expiration of Sanofi’s patent. The patents on Eloxatin expire between January 2013 and February 2016, according to Food and Drug Administration records.
The Lake Forest, Ill.-based company said the drug had sales of $1.5 billion last year, while IMS Health estimated sales of $1.7 billion for the 12-month period ended in June. Hospira’s launch came the same day as Sagent Pharmaceuticals’ launch of its own generic version of the drug.
Bristol-Myers Squibb, AstraZeneca expand diabetes deal
PRINCETON, N.J. — AstraZeneca paid $3.2 billion to Amylin Pharmaceuticals Thursday following the latter’s acquisition by Bristol-Myers Squibb, AstraZeneca and Bristol said.
The payment was made as part of the expansion of a deal between the drug manufacturers made in 2007 to develop diabetes drugs. Bristol announced Wednesday that it had completed its acquisition of Amylin, making the San Diego-based drug maker a wholly owned subsidiary.
AstraZeneca also said that pending regulatory approval, it would exercise certain rights over Amylin’s portfolio that it was granted as part of the deal with Bristol, paying Bristol $135 million once it is cleared to do so.